The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells
Open accessAbstract
Neuroendocrine (NE) differentiation in prostatic adenocarcinomas has been reported to be an early marker for development of androgen independence. Secretion of mitogenic peptides from nondividing NE cells is thought to contribute to a more aggressive disease by promoting the proliferation of surrounding tumor cells. We undertook studies to determine whether the prostate cancer cell line LNCaP could be induced to acquire NE characteristics by treatment with agents that are found in the complex environment in which progression of prostate cancer towards androgen independence occurs. We found that cotreatment of LNCaP cells with agents that signal through cyclic AMP-dependent protein kinase (PKA), such as epinephrine and forskolin, and with the cytokine interleukin-6 (IL-6) promoted the acquisition of an NE morphological phenotype above that seen with single agents. Convergent IL-6 and PKA signaling also resulted in potentiated mitogen-activated protein kinase (MAPK) activation without affecting the level of signal transducer and activator of transcription or PKA activation observed with these agents alone. Cotreatment with epinephrine and IL-6 synergistically increased c-fos transcription as well as transcription from the beta4 nicotinic acetylcholine receptor subunit promoter. Potentiated transcription from these elements was shown to be dependent on the MAPK pathway. Most importantly, cotreatment with PKA activators and IL-6 resulted in increased secretion of mitogenic neuropeptides. These results indicate that PKA and IL-6 signaling participates in gene transcriptional changes that reflect acquisition of an NE phenotype by LNCaP cells and suggest that similar signaling mechanisms, particularly at sites of metastasis, may be responsible for the increased NE content of many advanced prostate carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Cited by
Active Nanodiamond Hydrogels for Chemotherapeutic Delivery
Huang, H., Pierstorff, E., Osawa, E., & Ho, D. (2007) · Nano Letters · doi:10.1021/nl071521o · Cited by 556
Complex roles of cAMP–PKA–CREB signaling in cancer
Zhang, H., Kong, Q., Wang, J., Jiang, Y., & Hua, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00191-1 · Cited by 466
Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model
Kaplan‐Lefko, P. J., Chen, T., Ittmann, M. M., Barrios, R. J., Ayala, G. E., Huss, W. J., Maddison, L. A., Foster, B. A., & Greenberg, N. M. (2003) · The Prostate · doi:10.1002/pros.10215 · Cited by 438
Michalaki, V, Syrigos, K., Charles, P., & Waxman, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601814 · Cited by 406
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269
Metadata
- Authors
- Deeble, P. D., Murphy, D. J., Parsons, S. J., & Cox, M. E.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2001-12-01
- Volume
- 21
- Issue
- 24
- Pages
- 8471-8482
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2155062006
- Cited by
- 185
- References
- 1
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells. https://app.cochat.ai/papers/10.1128/mcb.21.24.8471-8482.2001
- The paper
- Deeble, P. D., Murphy, D. J., Parsons, S. J., & Cox, M. E. (2001). Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells. Molecular and Cellular Biology. https://doi.org/10.1128/mcb.21.24.8471-8482.2001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.